NASDAQ$SGHT
Sight Sciences Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported strong commercial results, FDA clearances, significant progress across clinical trials, and R&D advancements.
Sight Sciences reported a strong fourth quarter and full year 2021, with significant revenue growth and gross margin expansion. The company achieved FDA clearances for OMNI and TearCare, made progress in clinical trials, and advanced R&D efforts.
- Generated fourth quarter 2021 total revenue of $14.7 million, an increase of 63% compared to the prior year period.
- Expanded total gross margin to 87% in the fourth quarter 2021 versus 74% in the prior year period.
- Received FDA 510(k) Clearance of the TearCare® System for treatment of Meibomian Gland Disease (MGD).
- Completed the largest medical technology IPO of 2021, raising $276 million.
Headline financials
Revenue & EPS history
Sight Sciences · Revenue · Quarterly
$14.7M
Revenue by segment
Sight Sciences · $14.7M total across 2 segments · Q4 2021
- Interventional Glaucoma$13.9M+59.8%94.6%
- Interventional Dry Eye$800K+166.7%5.4%
Forward guidance
Sight Sciences projects revenue for the full year 2022 to range from $67 million to $75 million, which represents approximately 45% growth compared to 2021 using the midpoint of the range.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2021
+3.0%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+5.0%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+60.9%
Q3 2022
Best reaction
-26.9%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.7% | +22.6% | +2.5% | |
| Q4 2025 | -26.9% | -25.9% | -34.9% | |
| Q3 2025 | +16.0% | +54.4% | +61.0% | |
| Q1 2025 | +1.3% | +8.3% | +38.6% | |
| Q4 2024 | +2.9% | +15.3% | -5.0% | |
| Q3 2024 | -17.1% | -17.1% | -24.1% | |
| Q2 2024 | -18.9% | -29.4% | -13.0% | |
| Q1 2024 | +6.6% | +1.1% | +17.4% | |
| Q4 2023 | +6.8% | -4.4% | +21.4% | |
| Q3 2023 | +19.8% | +2.0% | +54.1% | |
| Q2 2023 | +11.0% | +4.1% | -16.0% | |
| Q1 2023 | -0.4% | +0.6% | -25.1% | |
| Q4 2022 | +4.9% | -2.3% | -5.8% | |
| Q3 2022 | +60.9% | +50.4% | +72.9% | |
| Q2 2022 | -3.9% | -16.1% | -26.2% | |
| Q1 2022 | +11.2% | +23.9% | +59.2% | |
| Q4 2021 | -10.1% | -6.1% | -45.5% | |
| Q3 2021 | -2.4% | -5.8% | -20.6% | |
| Q2 2021 | -4.7% | +0.1% | -15.9% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro